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Background
The Human Immunodeficiency virus type 1 (HIV-1)
protease (PR) and reverse transcriptase (RT) are key
enzymes in viral replication and major target of Antire-
troviral (ARV) therapy. The mechanisms of resistance
mainly involve mutations altering the interaction of viral
enzymes and inhibitors. Recent studies reveal that,
besides the enzymes-encoding ones, other regions might
contribute to the development of resistance. In particu-
lar, some specific cleavage and non-cleavage site muta-
tions in Gag increase the replication ability of mutant
viruses. The effect of amino acid substitutions in differ-
ent domains of Gag selected in vivo on viral replication,
remains to be elucidated. In attempt to clarify this
aspect, we analyzed clinical samples of HIV-1 infected
patients failing PR Inhibitor (PI) and RT Inhibitor (RTI)
treatment among a cohort of five infectious diseases
units located in Veneto in northeastern Italy.
Materials and methods
Plasma and PBMCs samples from ARV treatment patients
were used for gag and pol gene PCR amplification and
sequencing. Selected patient PCR-derived gag products
were adopted to reconstitute recombinant HIV-1 viruses
in an otherwise wildtype background (HIV-1 LAI). Gag
processing experiments, single-cycle infectivity assay and
replication kinetics were performed.
Results
We analyzed the gag and pol sequences derived from
clinical samples of HIV-1 infected patients failing PR
Inhibitors (PIs) and RT Inhibitors (RTIs). Besides poly-
morphisms and multiple amino acid substitutions asso-
ciated with inhibitor resistance, genotypic analyses have
identified insertions within the Gag at the level of the
matrix domain and the p6 domains. The effect of these
mutations have been examined in terms of: (i) Gag and
Gag-Pol processing and particle release; (ii) virus infec-
tivity as well as iii) viral replication capacity.
Conclusions
Our results contribute to better characterizing the role
of Gag and the relationship to PR and RT in resistance
development, their relevance in viral replication and
evolution in the presence or in the absence of drugs.
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